entinostat has been researched along with Multiple Myeloma in 7 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Entinostat, a selective class I inhibitor of histone deacetylase (HDAC), exerts anti-tumor activity in various cancer types, including multiple myeloma (MM)." | 7.79 | Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. ( Cai, B; Gao, C; Huang, J; Lee, CK; Liu, B; Lyu, H; Wang, S, 2013) |
| " Entinostat, a selective class I inhibitor of histone deacetylase (HDAC), exerts anti-tumor activity in various cancer types, including multiple myeloma (MM)." | 3.79 | Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. ( Cai, B; Gao, C; Huang, J; Lee, CK; Liu, B; Lyu, H; Wang, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ferro, A | 1 |
| Graikioti, D | 1 |
| Gezer, E | 1 |
| Athanassopoulos, CM | 1 |
| Cuendet, M | 1 |
| Wang, B | 1 |
| Lyu, H | 2 |
| Pei, S | 1 |
| Song, D | 1 |
| Ni, J | 1 |
| Liu, B | 2 |
| Cai, B | 1 |
| Huang, J | 1 |
| Wang, S | 1 |
| Lee, CK | 1 |
| Gao, C | 1 |
| Simmons, JK | 1 |
| Patel, J | 1 |
| Michalowski, A | 1 |
| Zhang, S | 1 |
| Wei, BR | 1 |
| Sullivan, P | 1 |
| Gamache, B | 1 |
| Felsenstein, K | 1 |
| Kuehl, WM | 1 |
| Simpson, RM | 1 |
| Zingone, A | 1 |
| Landgren, O | 1 |
| Mock, BA | 1 |
| Hentati-Kallel, M | 1 |
| Le Jan, S | 1 |
| Bernard, P | 1 |
| Antonicelli, F | 1 |
| Trussardi-Régnier, A | 1 |
| Ma, J | 2 |
| Zhao, M | 2 |
| Yu, XD | 2 |
| Wang, ZH | 1 |
7 other studies available for entinostat and Multiple Myeloma
| Article | Year |
|---|---|
Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Histo | 2023 |
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Prolif | 2018 |
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Topics: Apoptosis; Bendamustine Hydrochloride; Benzamides; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumo | 2013 |
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Topics: Animals; Benzamides; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Lymphoma, B-Cell; Mec | 2014 |
Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines.
Topics: Benzamides; Cell Line; Dexamethasone; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expressio | 2017 |
[Effects of histone deacetylase inhibitor MS-275 on expression of survivin and NF-kappaB in the human myeloma cell line U266 cells].
Topics: Apoptosis; Benzamides; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kina | 2009 |
[MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].
Topics: Acetylation; Apoptosis; Benzamides; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyc | 2009 |